EU/3/20/2370 : Orphan designation for the treatment of hepatocellular carcinoma
Tremelimumab
Table of contents
Overview
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2022 on request of the Sponsor.
On 9 December 2020, orphan designation EU/3/20/2370 was granted by the European Commission to AstraZeneca AB, Sweden, for tremelimumab for the treatment of hepatocellular carcinoma.
Key facts
Active substance |
Tremelimumab
|
Intended use |
Treatment of hepatocellular carcinoma
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/20/2370
|
Date of designation |
09/12/2020
|
Sponsor |
AstraZeneca AB |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
December 2022 | Product withdrawn from the Union Register of orphan medicinal products on request of the Sponsor. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: